Plasma Low-Molecular-Weight Proteome Profiling Identified Neuropeptide-Y as a Prostate Cancer Biomarker Polypeptide

2013 ◽  
Vol 12 (10) ◽  
pp. 4497-4506 ◽  
Author(s):  
Koji Ueda ◽  
Ayako Tatsuguchi ◽  
Naomi Saichi ◽  
Atsuhiko Toyama ◽  
Kenji Tamura ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Molecular Weight ◽  
Neuropeptide Y ◽  
Cancer Biomarker ◽  
Low Molecular Weight ◽  
Proteome Profiling ◽  
Low Molecular Weight Proteome

Cancer biomarker discoveryvia low molecular weight serum proteome profiling – Where is the tumor?

2007 ◽  
Vol 1 (12) ◽  
pp. 1545-1558 ◽  
Author(s):  
Michael T. Davis ◽  
Paul Auger ◽  
Chris Spahr ◽  
Scott D. Patterson
Keyword(s):  
Molecular Weight ◽  
Cancer Biomarker ◽  
Low Molecular Weight ◽  
Proteome Profiling ◽  
Serum Proteome

A LOW MOLECULAR WEIGHT FACTOR IN FETAL CALF SERUM INHIBITS THE PROGRESSION OF PROSTATE CANCER CELLS THROUGH S PHASE

2000 ◽  
Vol 28 (5) ◽  
pp. A369-A369
Author(s):  
P. V. G. Reddy ◽  
M. Menon ◽  
E. R. Barrack
Keyword(s):  
Prostate Cancer ◽  
Molecular Weight ◽  
Cancer Cells ◽  
Fetal Calf Serum ◽  
Calf Serum ◽  
S Phase ◽  
Low Molecular Weight ◽  
Weight Factor ◽  
Prostate Cancer Cells

scholarly journals A targeted low molecular weight near-infrared fluorescent probe for prostate cancer

2010 ◽  
Vol 20 (23) ◽  
pp. 7124-7126 ◽  
Author(s):  
Tiancheng Liu ◽  
Lisa Y. Wu ◽  
Mark R. Hopkins ◽  
Joseph K. Choi ◽  
Clifford E. Berkman
Keyword(s):  
Prostate Cancer ◽  
Molecular Weight ◽  
Fluorescent Probe ◽  
Near Infrared ◽  
Low Molecular Weight

scholarly journals Preclinical Evaluation of 203/212Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer

2019 ◽  
Vol 61 (1) ◽  
pp. 80-88 ◽  
Author(s):  
Sangeeta Ray Banerjee ◽  
Il Minn ◽  
Vivek Kumar ◽  
Anders Josefsson ◽  
Ala Lisok ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Molecular Weight ◽  
Low Molecular Weight ◽  
Preclinical Evaluation ◽  
Low Molecular Weight Compounds ◽  
Radiopharmaceutical Therapy

Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer

2004 ◽  
Vol 22 (13) ◽  
pp. 2532-2539 ◽  
Author(s):  
William L. Dahut ◽  
James L. Gulley ◽  
Philip M. Arlen ◽  
Yinong Liu ◽  
Katherine M. Fedenko ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Molecular Weight ◽  
Phase Ii ◽  
Low Molecular Weight Heparin ◽  
Phase Ii Trial ◽  
Low Molecular Weight ◽  
Randomized Phase Ii ◽  
The Impact ◽  
Docetaxel Group ◽  
Androgen Independent

Purpose Both docetaxel and thalidomide have demonstrated activity in androgen-independent prostate cancer (AIPC). We compared the efficacy of docetaxel to docetaxel plus thalidomide in patients with AIPC. Methods Seventy-five patients with chemotherapy-naïve metastatic AIPC were randomly assigned to receive either docetaxel 30 mg/m2 intravenously every week for 3 consecutive weeks, followed by a 1-week rest period (n = 25); or docetaxel at the same dose and schedule, plus thalidomide 200 mg orally each day (n = 50). Prostate-specific antigen (PSA) consensus criteria and radiographic scans were used to determine the proportion of patients with a PSA decline, and time to progression. Results After a median potential follow-up time of 26.4 months, the proportion of patients with a greater than 50% decline in PSA was higher in the docetaxel/thalidomide group (53% in the combined group, 37% in docetaxel-alone arm). The median progression-free survival in the docetaxel group was 3.7 months and 5.9 months in the combined group (P = .32). At 18 months, overall survival in the docetaxel group was 42.9% and 68.2% in the combined group. Toxicities in both groups were manageable after administration of prophylactic low-molecular-weight heparin in the combination group. Conclusion In this randomized phase II trial, the addition of thalidomide to docetaxel resulted in an encouraging PSA decline rate and overall median survival rate in patients with metastatic AIPC. After the prophylactic low-molecular-weight heparin was instituted to prevent venous thromboses, the combination regimen was well tolerated. Larger randomized trials are warranted to assess the impact of this combination.

Mining the low molecular weight proteome of blood

2007 ◽  
Vol 1 (8) ◽  
pp. 758-768 ◽  
Author(s):  
Richard R. Drake ◽  
Lisa Cazares ◽  
O. John Semmes
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight ◽  
Low Molecular Weight Proteome

Core-shell silica microsphere-based trypsin nanoreactor for low molecular-weight proteome analysis

2017 ◽  
Vol 985 ◽  
pp. 194-201 ◽  
Author(s):  
Yujia Wang ◽  
Shucheng Sun ◽  
Irfan Azhar ◽  
Qian Zhang ◽  
Qishu Qu ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Proteome Analysis ◽  
Core Shell ◽  
Low Molecular Weight ◽  
Silica Microsphere ◽  
Low Molecular Weight Proteome

Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential

2016 ◽  
Vol 69 (4) ◽  
pp. 710-719 ◽  
Author(s):  
Roberta R. Ruela-de-Sousa ◽  
Elmer Hoekstra ◽  
A. Marije Hoogland ◽  
Karla C. Souza Queiroz ◽  
Maikel P. Peppelenbosch ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Molecular Weight ◽  
Protein Tyrosine Phosphatase ◽  
Tyrosine Phosphatase ◽  
Metastatic Potential ◽  
Low Molecular Weight ◽  
Molecular Weight Protein ◽  
Weight Protein ◽  
Low Molecular Weight Protein ◽  
Cancer Outcome

An integrated serum proteomic approach capable of monitoring the low molecular weight proteome with sequencing of intermediate to large peptides

2009 ◽  
Vol 23 (17) ◽  
pp. 2685-2696 ◽  
Author(s):  
Karen Merrell ◽  
Craig D. Thulin ◽  
M. Sean Esplin ◽  
Steven W. Graves
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight ◽  
Proteomic Approach ◽  
Low Molecular Weight Proteome
Sign in / Sign up

Export Citation Format

Share Document